The broad nature of insulin resistant glucose metabolism in skeletal muscle of patients with type 2 diabetes suggests a defect in the proximal part of the insulin signaling network. We sought to identify the pathways compromised in insulin resistance and to test the effect of moderate exercise on whole-body and cellular insulin action. We conducted euglycemic clamps and muscle biopsies on type 2 diabetic patients, obese nondiabetics and lean controls, with and without a single bout of exercise. Insulin stimulation of the phosphatidylinositol 3-kinase (PI 3-kinase) pathway, as measured by phosphorylation of the insulin receptor and IRS-1 and by IRS protein association with p85 and with PI 3-kinase, was dramatically reduced in obese nondiabetics and virtually absent in type 2 diabetic patients. Insulin stimulation of the MAP kinase pathway was normal in obese and diabetic subjects. Insulin stimulation of glucose-disposal correlated with association of p85 with IRS-1. Exercise 24 hours before the euglycemic clamp increased phosphorylation of insulin receptor and IRS-1 in obese and diabetic subjects but did not increase glucose uptake or PI 3-kinase association with IRS-1 upon insulin stimulation. Thus, insulin resistance differentially affects the PI 3-kinase and MAP kinase signaling pathways, and insulin-stimulated IRS-1–association with PI 3-kinase defines a key step in insulin resistance.

Find the latest version:

http://jci.me/7535-pdf
Insulin resistance differentially affects the PI 3-kinase– and MAP kinase–mediated signaling in human muscle

Kenneth Cusi,1 Katsumi Maezono,1 Abdullah Osman,1 Merri Pendergrass,1 Mary Elizabeth Patti,2 Thongchai Pratipanawatr,1 Ralph A. DeFronzo,1 C. Ronald Kahn,2 and Lawrence J. Mandarino1

1Division of Diabetes, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
2The Joslin Diabetes Center and Harvard Medical School, Boston, Massachusetts 02215, USA

Address correspondence to: Lawrence J. Mandarino, Division of Diabetes, Department of Medicine, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA.
Phone: (210) 567-6691; Fax: (210) 567-6554; E-mail: mandarino@uthscsa.edu.

Katsumi Maezono’s current address is: Ajinomoto Co. Inc., 214 Maeda-Cho, Totsuka-Ku, Yokohama 244-0804 Japan.

Merri Pendergrass’s current address is: Tulane University Medical Center, School of Medicine, Department of Medicine SL53, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.

Kenneth Cusi, Katsumi Maezono, and Abdullah Osman contributed equally to this work.

Received for publication June 8, 1999, and accepted in revised form December 15, 1999.

The broad nature of insulin resistant glucose metabolism in skeletal muscle of patients with type 2 diabetes suggests a defect in the proximal part of the insulin signaling network. We sought to identify the pathways compromised in insulin resistance and to test the effect of moderate exercise on whole-body and cellular insulin action. We conducted euglycemic clamps and muscle biopsies on type 2 diabetic patients, obese nondiabetics and lean controls, with and without a single bout of exercise. Insulin stimulation of the phosphatidylinositol 3-kinase (PI 3-kinase) pathway, as measured by phosphorylation of the insulin receptor and IRS-1 and by IRS protein association with p85 and with PI 3-kinase, was dramatically reduced in obese nondiabetics and virtually absent in type 2 diabetic patients. Insulin stimulation of the MAP kinase pathway was normal in obese and diabetic subjects. Insulin stimulation of glucose disposal correlated with association of p85 with IRS-1. Exercise 24 hours before the euglycemic clamp increased phosphorylation of insulin receptor and IRS-1 in obese and diabetic subjects but did not increase glucose uptake or PI 3-kinase association with IRS-1 upon insulin stimulation. Thus, insulin resistance differentially affects the PI 3-kinase and MAP kinase signaling pathways, and insulin-stimulated IRS-1–association with PI 3-kinase defines a key step in insulin resistance.


Introduction

Insulin resistance characterizes skeletal muscle of patients with type 2 diabetes mellitus and obesity and affects all the metabolic actions of insulin, including glucose transport, hexokinase activity and gene expression, glycogen synthesis, and glucose oxidation (1–5). Because insulin resistance globally affects glucose metabolism, it can be reasoned that a proximal defect, such as in insulin receptor signaling, causes these metabolic abnormalities in muscle. Knowledge of the details of insulin receptor signaling has grown dramatically in recent years. Once insulin binds to its receptor and activates the tyrosine kinase activity of the insulin receptor β subunit, insulin signaling pathways diverge. One pathway proceeds through the insulin receptor substrates IRS-1 and IRS-2 and depends on activation of the enzyme phosphatidylinositol 3-kinase (PI 3-kinase). Another pathway proceeds through Grb2/Sos and ras, leading to activation of the MAP kinase isoforms ERK1 and ERK2. Insulin produces most of its metabolic actions through the PI 3-kinase pathway (6–8). In contrast, inhibition of ERK activation does not reduce insulin-stimulated glucose transport or glycogen synthesis (9).

Details of insulin receptor signaling have been revealed by the use of a variety of in vitro techniques. However, several studies also have examined how insulin resistance alters insulin receptor signaling in vivo in human muscle. Using glucose clamps and muscle biopsies or other techniques, investigators have described abnormalities in insulin-stimulated insulin receptor signaling in muscle from insulin-resistant patients (10–14). In many of these studies, the use of supraphysiological insulin concentrations clouds the interpretation of the results. Moreover, no study to date has reported results concerning the effect of insulin on the MAP kinase pathway in human muscle in vivo, so it is unclear whether insulin resistance also affects the MAP kinase pathway.

Muscle contraction and insulin produce many of the same effects on glucose metabolism. For example, mus-
cle contraction induces GLUT4 translocation to the cell membrane, activates glycogen synthase, and induces hexokinase II gene expression, independently of insulin (15–19). Chronic exercise training also improves insulin sensitivity (20–23). Despite these close similarities in their effects on glucose metabolism, muscle contraction and insulin use different signaling pathways. Muscle contraction itself does not increase the magnitude of any insulin signaling events in the PI 3-kinase pathway (16, 24–27). However, the fact remains that even a single bout of vigorous exercise can enhance insulin action (28, 29). It remains unknown, however, whether a single session of moderate exercise can enhance subsequent insulin stimulation of insulin receptor signaling in humans, at a time when the acute effects of exercise on blood flow or other factors has subsided.

The present study was performed to determine first, whether insulin resistance equally affects the PI 3-kinase and MAP kinase pathways, and second, how a single bout of moderate exercise alters whole-body and cellular insulin action in type 2 diabetes. The euglycemic clamp technique was combined with muscle biopsies for these purposes. The results show that in obese and type 2 diabetic patients, insulin resistance is present at the level of association of IRS proteins with the regulatory subunit of PI 3-kinase, but does not involve the MAP kinase signaling pathway. A single bout of moderate exercise improves the response of early elements in insulin receptor signaling, but does not affect the abnormality in association of PI 3-kinase with IRS-1 or insulin-stimulated glucose disposal in type 2 diabetes. Therefore, decreased association of PI 3-kinase with IRS-1 is a key defect in insulin resistance in skeletal muscle in type 2 diabetes.

Methods

Subjects. A total of 27 volunteers (8 lean control subjects, 9 obese nondiabetics, and 10 patients with type 2 diabetes) participated. Their clinical characteristics are shown in Table 1. Normal glucose tolerance was confirmed in obese and control subjects by a 75-g oral glucose tolerance test using American Diabetes Association criteria. The diabetic patients were being treated with diet (n = 2) or oral hypoglycemic agents (n = 8). Oral agents were discontinued 48 hours before the study. No diabetic subject was receiving insulin. Other than diabetes, none of the subjects had any significant medical problems, and none were taking any medications that are known to affect glucose metabolism. Subjects were instructed to maintain their usual diet for at least 3 days and not to engage in vigorous exercise for at least 2 days before study. The purpose, nature, and potential risks of the

Figure 1
Representative immunoblots. Top panel: Effect of insulin infusion in lean, obese nondiabetic, and type 2 diabetic subjects on insulin receptor (a) and IRS-1 (b) tyrosine phosphorylation, and the association of p85 with IRS-1 (c). Phosphotyrosine content of specific proteins was determined by immunoprecipitation with insulin receptor or IRS-1 antibodies followed by immunoblot analysis with antiphosphotyrosine antibodies. The association of p85 with IRS-1 was determined by immunoblot analysis of anti–IRS-1 immunoprecipitates. Bottom panel: Effect of insulin infusion in lean, obese nondiabetic, and type 2 diabetic subjects on PI 3-kinase activity associated with IRS-1 (d) or p110 (e). PI 3-kinase activity was determined as described in the text in anti–IRS-1 immunoprecipitates; effect of insulin infusion on phosphorylation of ERK, determined by immunoblot analysis with an antiphosphoERK antibody (f). pTyr, phosphotyrosine.
study were explained to all subjects, and written consent was obtained before their participation. The protocol was approved by the Institutional Review Board of the University of Texas Health Science Center at San Antonio.

Study design. All studies were conducted in the General Clinical Research Center of the University of Texas, Health Science Center at San Antonio and began at 0730 hours after a 10-hour overnight fast. An antecubital vein was cannulated for infusion of insulin and glucose, and a hand vein was cannulated retrogradely and placed in a heated box (60°C) for sampling of arterialized blood. A hand vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insulin and glucose, and a leg vein was cannulated for infusion of insul

Table 1

<table>
<thead>
<tr>
<th>Subject characteristics</th>
<th>Age (yr)</th>
<th>Gender</th>
<th>Ethnicity</th>
<th>BMI (kg/m²)</th>
<th>Plasma glucose (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lean controls (n = 8)</td>
<td>34 ± 5</td>
<td>7/1</td>
<td>M/A</td>
<td>25.0 ± 2.0</td>
<td>87 ± 3</td>
</tr>
<tr>
<td>Obese nondiabetics (n = 9)</td>
<td>40 ± 3</td>
<td>4/5</td>
<td>M/A</td>
<td>34.2 ± 1.7</td>
<td>92 ± 2</td>
</tr>
<tr>
<td>Type 2 diabetics (n = 10)</td>
<td>48 ± 3a</td>
<td>5/5</td>
<td>M/A</td>
<td>30.0 ± 0.9a</td>
<td>152 ± 16</td>
</tr>
</tbody>
</table>

*P < 0.05 versus lean controls. Data are given as means ± SEM. Ethnicity: M, Mexican American; A, Anglo.
HPO<sub>4</sub>. The discs were washed once with acetone and air-dried, and the <sup>32</sup>P incorporated into myelin basic protein was measured by liquid scintillation counting. Specific kinase activity was determined by subtracting the radioactivity in the absence of substrate from that in the presence of substrate. Western blotting was performed on a portion of the immunoprecipitates, and the radioactivity was normalized for ERK-2 content.

**MEK1 activity.** MEK1 activity was assayed as described previously (34). Muscle protein (250 μg) was incubated with 1.25 μg/tube of anti-MEK1 mAb at 4°C for 3 hours followed by incubation with 50 μL of protein G-agarose beads for an additional 2 hours. Immunoprecipitates were washed, and the immune complexes were resuspended in MEK1 kinase buffer containing 50 μM ATP, 10 μCi/sample of [γ-<sup>32</sup>P]ATP (6,000 cpm/pmol), and a recombinant kinase-inactive mouse GST-MAPK (1.4 μg/tube) as substrate. The suspension was incubated with agitation for 30 minutes at 30°C, and the reaction was stopped by adding 40 μL of SDS sample buffer. Products were boiled for 5 minutes and resolved on 10% SDS-PAGE. The gel was dried, and phosphorylated GST-ERK2 bands (62 kDa) were quantified using a PhosphorImager and ImageQuant Software (Molecular Dynamics, Inc., California, USA).

**Glycogen synthase activity.** Glycogen synthase (GS) activity was assayed as described (5). Activity was determined in the presence of 0.1 (GS<sub>0.1</sub>) and 10 (GS<sub>10</sub>) mM glucose 6-phosphate (G6P). GS fractional velocity (GS<sub>f</sub>) is the ratio GS<sub>10</sub>/GS<sub>0.1</sub>.

**Materials.** Polyclonal anti-insulin receptor β subunit, anti–IRS-1, anti-p85, anti–p110-alpha, anti–p110-β, anti–ERK2, and monoclonal antiphosphotyrosine (4G10) antibodies, and GST-MAP kinase were purchased from Upstate Biotechnology (Lake Placid, New York, USA). The polyclonal anti–IRS-2 (JD250) antibody was from Upstate Biotechnology (Lake Placid, New York, USA). Regular human recombinant insulin was obtained from Eli Lilly & Co. (Indianapolis, Indiana, USA). Phosphocellulose paper (p81) and Silica gel 60 TLC plates were purchased from Whatman, Inc. (Clifton, New Jersey, USA). Reagents for SDS-PAGE were from Bio-Rad Laboratories Inc. (Richmond, California, USA). The ECL detection system and secondary antibodies were purchased from Amersham Life Science (Arlington Heights, Illinois, USA). Anti-MEK1 antibody was from Transduction Laboratories (Lexington, Kentucky, USA). All other reagents were purchased from Sigma Chemical Co. (St. Louis, Missouri, USA).

**Statistical methods.** The data are presented as means ± SE. The ability of insulin treatment to increase insulin signaling events, glycogen synthase activity, or glucose disposal was compared with basal values using 1-tailed paired t tests. Multiple comparisons among groups and time-course studies were tested by ANOVA, using StatView software (version 4.0; SAS Inc., Cary, North Carolina, USA). Correlation analysis was performed by the Pearson product moment method. Stepwise multiple regression analysis was done using Minitab Statistical Software (Minitab, Inc., State College, Pennsylvania, USA).

## Results

**Metabolic characteristics and insulin stimulation of glucose disposal.** Metabolic data and PI 3-kinase signaling data from 5 of the 8 control subjects has been reported (27). Euglycemic clamp experiments were performed to assess the effects of insulin on glucose metabolism (Tables 1 and 2). Plasma insulin concentrations were 7 ± 1, 13 ± 1, and 18 ± 1 μU/mL basally and 69 ± 5, 96 ± 5, and 92 ± 7 μU/mL during the euglycemic clamp in lean, obese, and diabetic subjects. Insulin increased glucose disposal in lean control and obese nondiabetic subjects (P < 0.05), but had no effect in the diabetic subjects. Basal hepatic glucose production (HGP) was increased in the diabetics (P < 0.05). Insulin suppressed HGP completely in the lean control subjects, but only by about 75% in the obese nondiabetics and diabetics. The ability of a bout of moderate exercise (65% of VO<sub>2max</sub>) to influence subsequent insulin stimulation of insulin receptor signaling 24 hours later was studied in 7 of 9 obese nondiabetic controls and all 10 type 2 diabetics. The obese nondiabetics and type 2 diabetics who participated in the exercise studies had a VO<sub>2max</sub> of 24.1 ± 2.7 mL/kg per minute (2.16 ± 0.30 L/min) and 21.9 ± 1.5 mL/kg per minute (1.79 ± 0.13 L/min), respectively (P –
Insulin infusion at a rate of 40 mU/(m²/min) was performed in the obese controls and diabetics. Basal GS₀.₁ activity and insulin stimulation of glycogen synthase activity were reduced significantly in the diabetics. The difference was not statistically significant. Basal GS₀.₁ activity and insulin stimulation of glycogen synthase activity were reduced significantly in the diabetics. Exercise increased GS₀.₁ in the obese nondiabetics, but had no effect on glucose disposal in the diabetics. Exercise increased GS₀.₁ basally and after insulin infusion in the obese controls and diabetics.

**Glycogen synthase activity.** Insulin infusion significantly increased GS₀.₁, but not GS₁₀, activity in lean control subjects to a value 152 ± 13 % of basal values (Table 3). Insulin infusion also increased GS₀.₁ activity in obese nondiabetics to a lesser degree than in lean controls. This difference was not statistically significant. Basal GS₀.₁, activity and insulin stimulation of glycogen synthase activity were reduced significantly in the diabetics. Exercise increased GS₀.₁ basally and after insulin infusion in the obese controls and diabetics.

**Time course of insulin stimulation of insulin receptor and IRS-1 tyrosine phosphorylation.** In 2 subjects, muscle biopsies were performed before and after 15 and 30 minutes of infusion of insulin at a rate of 40 mU/(m²/minute). Insulin stimulated both insulin receptor and IRS-1 tyrosine phosphorylation by 15 minutes, and this level of phosphorylation was sustained for at least 30 minutes.

**Insulin receptor and IRS-1 tyrosine phosphorylation: effect of obesity, diabetes, and exercise.** The ability of insulin to increase tyrosine phosphorylation of the insulin receptor was assayed by immunoprecipitation of insulin receptors followed by immunoblot analysis with an antiphosphotyrosine antibody. Data are given in Table 4, and representative immunoblots are shown in Figure 1. The modest (about 50%), but significant (P < 0.05), increase in phosphotyrosine content of the receptor β subunit in lean control subjects after insulin stimulation reflects the physiological nature of the insulin stimulation. In contrast, hyperinsulinemia did not increase tyrosine phosphorylation of the insulin receptor β subunit in either obese nondiabetic or type 2 diabetic patients. Tyrosine phosphorylation of IRS-1 was increased after insulin stimulation by 2-fold in lean control subjects (P < 0.05), but there was no effect in the diabetics (Table 4). In contrast to the results with the insulin receptor, insulin increased IRS-1 tyrosine phosphorylation significantly in obese nondiabetics (P < 0.05). Prior exercise significantly increased insulin-stimulated insulin receptor tyrosine phosphorylation in both groups (161 ± 18 and 134 ± 21% of basal values for obese and diabetic subjects; P < 0.05 for both). Neither group was restored fully to normal values, however (Figure 2). Exercise significantly reduced basal insulin receptor tyrosine phosphorylation, compared with pre-exercise values, in the diabetics (Figure 2; P < 0.05). Exercise also significantly improved the response of IRS-1 tyrosine phosphorylation to insulin in the diabetic group (P < 0.05), but this was still significantly less than that of lean control subjects who were studied without exercise (P < 0.05). Similar to insulin receptor phosphorylation, this was due primarily to decreased basal tyrosine phosphorylation. Insulin did not affect insulin receptor or IRS-1 protein. Insulin receptor protein was 2.42 ± 0.32, 2.70 ± 0.30, and 2.82 ± 0.26 arbitrary units, and IRS-1 protein was 0.97 ± 0.07, 0.95 ± 0.12, and 1.04 ± 0.07 arbitrary units in lean, obese, and diabetic subjects, respectively.

**Association of p85 and PI 3-kinase activity with IRS-1.** The association of the p85 regulatory subunit of PI 3-kinase with IRS-1 was determined by quantifying p85 protein in IRS-1 immunoprecipitates (Figure 1 and Table 4). Insulin stimulated the association of p85 with IRS-1 by 62 ± 12%, and this was similar in lean control and obese nondiabetics. Insulin did not increase the association of p85 with IRS-1 in the diabetics. The pattern of insulin stimulation of PI 3-kinase activity associated with IRS-1 paralleled p85 binding to IRS-1. Insulin stimulated the association of PI 3-kinase activity with IRS-1 in lean control (2.13 ± 0.42 fold; P < 0.01) and obese nondiabetic (1.68 ± 0.20 fold; P < 0.05) subjects but did not significantly increase the association of PI 3-kinase activity with IRS-1 in muscle from the type 2 diabetic patients. The activity of PI 3-kinase was...
also determined in p110 immunoprecipitates in order to gain an estimate of an overall effect of insulin on PI 3-kinase activity. Insulin increased PI 3-kinase activity in p110 immunoprecipitates significantly in lean subjects (2.81 ± 0.70 fold; \( P < 0.05 \)), but not in obese nondiabetics or diabetics (Table 4). During insulin stimulation, PI 3-kinase activity was decreased in both the obese nondiabetics and type 2 diabetic patients compared with lean controls (\( P < 0.05 \)). Exercise only modestly improved insulin-stimulated IRS-1–associated p85 in the obese nondiabetics (130 ± 15% of basal; \( P < 0.05 \); Figure 3) and not at all in the diabetics. Exercise did not improve insulin-stimulated IRS-1–associated PI 3-kinase activity in either the obese or diabetic subjects (Figure 3).

IRS-2 has been proposed to function as a compensatory signaling protein for IRS-1. The association of the p85 regulatory subunit of PI 3-kinase with IRS-2 was determined by quantifying p85 protein in IRS-2 immunoprecipitates using immunoblot analysis in 5 lean control subjects and in 6 each of the obese and diabetic subjects. In lean controls, insulin increased the association of p85 with IRS-2 from a basal value of 0.124 ± 0.031 to 0.178 ± 0.029 (\( P < 0.05 \)). In obese nondiabetics, insulin infusion increased the association of p85 with IRS-2 from 0.171 ± 0.036 to 0.243 ± 0.046 (\( P < 0.05 \)). Insulin infusion did not increase the association of p85 with IRS-2 in diabetics (0.203 ± 0.040 basally versus 0.206 ± 0.032 after insulin).

MAP kinase pathway activity. MAP kinase pathway activity was assessed in 3 ways. Phosphorylation of ERK1 and ERK2 was assayed using immunoblot analysis with an antibody directed against the doubly phosphorylated ERKs. ERK activity was determined by the ability of ERK2 immunoprecipitates to phosphorylate myelin basic protein, and MEK1 activity was assayed by the ability of MEK1 immunoprecipitates to phosphorylate an inactive recombinant GST-ERK protein. The results are given in Table 5, and representative immunoblots are shown in Figure 1. In contrast to the defective insulin receptor signaling pathway through IRS-1 and PI 3-kinase, insulin increased ERK phosphorylation, ERK activity, and MEK1 activity in insulin-resistant patients to the same extent as lean controls. There were no significant differences for ERK and MEK activities or ERK phosphorylation among the 3 groups. The effect of exercise on insulin stimulation of the MAP kinase pathway was different than that for the other signaling events. The responses of ERK phosphorylation, ERK activity, and MEK1 activity to insulin all were increased by exercise to values that exceeded the insulin-stimulated, but nonexercised, values in lean controls (Figure 4). Insulin had no effect on ERK2 protein content, which was 1.58 ± 0.11, 1.51 ± 0.27, and 1.58 ± 0.25 arbitrary units in lean, obese, and diabetic subjects, respectively.

In vitro insulin receptor tyrosine kinase activity and Shc phosphorylation. The MAP kinase pathway was activated by insulin in the diabetics despite the lack of a detectable insulin-stimulated increase in insulin receptor phosphorylation. To determine the potential tyrosine kinase activity of the insulin receptor, muscle homogenates in a subgroup of the control and diabetic subjects were exposed to insulin (100 ng/mL) in the presence of \(^{32}P\)ATP. Insulin receptors were immunoprecipitated and resolved by SDS-PAGE, and \(^{32}P\) content was quantified by PhosphorImage analysis. In lean controls (\( n = 6 \)), insulin increased the incorporation of \(^{32}P\) into insulin receptor protein from 1.39 ± 0.45 to 2.33 ± 0.95 arbitrary units (\( P < 0.05 \)). In diabetics (\( n = 6 \)), insulin increased incorporation of \(^{32}P\) into insulin receptor protein from 1.26 ± 0.48 to 2.12 ± 0.50 arbitrary units (\( P < 0.05 \)). To determine whether Shc is phosphorylated residues by insulin, muscle biopsy homogenates were immunoprecipitated with an anti-Shc antibody followed by immunoblot analysis with an antiphosphotyrosine antibody. Insulin increased Shc tyrosine phosphorylation from 9.05 ± 0.34 to 14.9 ± 0.61, from 10.1 ± 0.35 to 15.1 ± 0.40, and from 9.72 ± 0.47 to 15.8 ± 0.33 in lean con-
controls, obese nondiabetics, and diabetics, respectively (all arbitrary units, all \( P < 0.05 \), insulin versus basal).

**Correlations.** The associations between insulin stimulation of insulin signaling elements and glucose disposal were assessed by correlation analysis. Insulin-stimulated glucose disposal was positively correlated with the insulin-stimulated increment in glycogen synthase activity \((r = 0.457; P < 0.05)\), IRS-1 tyrosine phosphorylation \((r = 0.436; P < 0.05)\), and association of p85 with IRS-1 \((r = 0.424; P < 0.05)\). Multiple linear regression revealed that insulin-stimulated glucose disposal was independently correlated with glycogen synthase activity and association of p85 with IRS-1 \((r = 0.43; P < 0.005)\). Insulin stimulation of IRS-1 tyrosine phosphorylation was correlated with association of p85 with IRS-1 \((r = 0.806; P < 0.001)\) and with association of PI 3-kinase activity with IRS-1 \((r = 0.582; P < 0.01)\). Activation of the MAP kinase pathway was not correlated with insulin stimulation of glucose disposal.

**Discussion**

Previous studies have shown that obese and type 2 diabetic patients have reduced insulin receptor tyrosine kinase activity and reduced intracellular signaling compared with lean control subjects \((10–14, 26)\). However, these studies have not dissected the impact of insulin resistance on the divergent pathways of insulin action. The present study was undertaken, in part, to determine whether insulin resistance affects both the PI 3-kinase and MAP kinase pathways of insulin receptor signaling similarly, as these appear to be linked to different downstream effects; that is, PI 3-kinase is coupled to most metabolic actions, whereas MAP kinase may be linked to cell growth and gene expression \((6–9)\). Physiological hyperinsulinemia increased tyrosine phosphorylation of the insulin receptor and IRS-1 in lean controls to 150–200% of basal values. Obese nondiabetics had reduced insulin stimulation of these 2 early insulin receptor signaling events, and insulin had no significant effect on either insulin receptor or IRS-1 tyrosine phosphorylation in the type 2 diabetic patients. Furthermore, insulin activation of the association of p85 protein or PI 3-kinase activity was greatly reduced in obese and type 2 diabetic subjects compared with lean controls.

The lack of increase in tyrosine phosphorylation of the \( \beta \) subunit of the insulin receptor in the diabetics seems to represent a more profound abnormality than the moderate decrease in insulin receptor tyrosine kinase activity reported in other studies \((10)\). This may reflect the more physiological nature of the insulin stimulation in the present study or may be indirect evidence of increased activity of protein tyrosine phosphatases \((36, 37)\). To test whether insulin was able to stimulate the tyrosine kinase of the receptor \( \beta \) subunit, receptors were exposed to insulin and then immunoprecipitated while phosphatase activity was inhibited. Insulin increased receptor tyrosine kinase activity to

---

**Table 3**

Glycogen synthase activities

<table>
<thead>
<tr>
<th></th>
<th>No exercise</th>
<th></th>
<th>After exercise</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Basal</td>
<td>Insulin</td>
<td>Basal</td>
<td>Insulin</td>
</tr>
<tr>
<td>G6P (mM)</td>
<td>0.1</td>
<td>10</td>
<td>0.1</td>
<td>10</td>
</tr>
<tr>
<td>Lean controls</td>
<td>0.373 ± 0.057</td>
<td>2.71 ± 0.39</td>
<td>0.572 ± 0.112A</td>
<td>2.92 ± 0.42</td>
</tr>
<tr>
<td>Obese nondiabetics</td>
<td>0.382 ± 0.046</td>
<td>2.01 ± 0.22B</td>
<td>0.499 ± 0.054A</td>
<td>2.21 ± 0.15</td>
</tr>
<tr>
<td>Type 2 diabetics</td>
<td>0.273 ± 0.03B</td>
<td>1.99 ± 0.22B</td>
<td>0.354 ± 0.032A</td>
<td>1.91 ± 0.16B</td>
</tr>
</tbody>
</table>

\( \text{Insulin receptor phosphorylation} \)

<table>
<thead>
<tr>
<th>Lean controls (n = 8)</th>
<th>Obese nondiabetics (n = 9)</th>
<th>Type 2 diabetics (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin receptor phosphorylation</td>
<td>0.415 ± 0.077</td>
<td>0.624 ± 0.141A</td>
</tr>
<tr>
<td>IRS-1 phosphorylation</td>
<td>0.485 ± 0.073</td>
<td>0.875 ± 0.140A</td>
</tr>
<tr>
<td>p85 association with IRS-1</td>
<td>0.384 ± 0.053</td>
<td>0.623 ± 0.101A</td>
</tr>
<tr>
<td>IRS-1-associated PI 3-kinase activity</td>
<td>0.105 ± 0.017</td>
<td>0.218 ± 0.045A</td>
</tr>
<tr>
<td>Total (p110-associated)</td>
<td>0.845 ± 0.351</td>
<td>1.83 ± 0.60A</td>
</tr>
</tbody>
</table>

\( ^A P < 0.05 \) versus basal values. \( ^B P < 0.05 \) versus values in lean controls. \( ^C P < 0.05 \) versus values in obese nondiabetics. Data are given as means ± SEM. Insulin receptor and IRS-1 phosphorylation and p85 association with IRS-1 were determined by scanning densitometry following immunoprecipitation and immunoblot analysis, and the units are arbitrary density units. PI 3-kinase activity was determined as described in the text and expressed as arbitrary units relative to a pooled positive Jurkat cell control.
the same extent in diabetics and in lean control subjects. This indicates that the insulin receptor in the diabetics retains, at least in vitro, responsiveness to insulin. The fact that obese nondiabetic subjects have some detectable insulin stimulation of IRS-1 tyrosine phosphorylation even though insulin receptor phosphorylation was not significantly increased supports the concept that receptor tyrosine kinase activity is not reduced to as great an extent as insulin receptor tyrosine phosphorylation. Regardless, the present data indicate that there is profound resistance to insulin’s ability to activate the PI 3-kinase signaling pathway in obese and especially type 2 diabetic patients.

Recent studies suggest that an abnormality in IRS-1 function is not sufficient to produce insulin resistance that can lead to diabetes (38) but that an IRS-2 knockout mouse becomes hyperglycemic. In contrast, another study suggests that IRS-2 acts as a compensatory signaling protein for IRS-1 in adipocytes isolated from type 2 diabetics (39), in a similar way that it compensates for the loss of IRS-1 in the IRS-1 knockout mouse (35). To address this issue in human muscle, IRS-2 protein and insulin stimulation of the association of p85 protein with IRS-2 were assayed. The results show that although IRS-2 expression was found to be normal in the diabetics, insulin did not stimulate the association of p85 with IRS-2. This defect is similar to the IRS-1 abnormality observed here, and suggests that type 2 diabetes is characterized by a combined defect in IRS-1 and IRS-2 function.

The profound insulin resistance of the PI 3-kinase signaling pathway contrasts markedly with the ability of insulin to stimulate MAP kinase pathway activity in insulin-resistant individuals. Hyperinsulinemia increased MEK1 activity and ERK1/2 phosphorylation and activity to the same extent in lean controls as in insulin-resistant obese nondiabetic and type 2 diabetic patients. That is, insulin resistance does not affect the MAP kinase signaling pathway in vivo in humans. This finding of selective insulin resistance is similar to that recently observed in vasculature of Zucker fatty rats (40). Two possible reasons for this difference are alternate insulin signaling pathways and differential signal amplification. With regard to the former, the MAP kinase pathway can be activated either through Grb2/Sos interaction with IRS-1/2 or with Shc. Because IRS-1 tyrosine phosphorylation is dramatically reduced in the diabetics, it is possible that insulin activation of the MAP kinase pathway in vivo primarily occurs through Shc activation. Evidence from in vitro studies supports this concept (41). Like ERK and MEK activity, insulin stimulated Shc phosphorylation to the same extent in lean, obese, and type 2 diabetic subjects. We propose that in diabetes, insulin induces sufficient activation of the insulin receptor tyrosine kinase to increase Shc phosphorylation normally. It is also possible that differential signal amplification in the PI 3-kinase and MAP kinase pathways can explain their differing susceptibilities to the effects of insulin resistance.

Maintenance of insulin stimulation of the MAP kinase pathway in the presence of insulin resistance in the PI 3-kinase pathway may be important in the development or maintenance of insulin resistance. ERKs can phosphorylate IRS-1 on serine residues (42), and serine phosphorylation of IRS-1 and the insulin receptor itself has been implicated in desensitizing insulin receptor signaling (43). Continued ERK activity when IRS-1 function is already impaired could lead to a worsening of insulin resistance. Thus, the diabetic and obese subjects may have inappropriately high MAP kinase activity.

Another purpose of the present study was to gain evidence regarding which steps in insulin signaling have the greatest impact on insulin action. First, insulin stimu-
Table 5
Insulin receptor signaling through the MAP kinase pathway

<table>
<thead>
<tr>
<th></th>
<th>Lean controls</th>
<th>Obese nondiabetics</th>
<th>Type 2 diabetics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Basal</td>
<td>Insulin</td>
</tr>
<tr>
<td>ERK phosphorylation</td>
<td>0.659 ± 0.013</td>
<td>0.918 ± 0.009 A</td>
<td>0.652 ± 0.021</td>
</tr>
<tr>
<td>ERK activity</td>
<td>1.384 ± 0.327</td>
<td>2.420 ± 0.623 A</td>
<td>1.110 ± 0.316</td>
</tr>
<tr>
<td>MEK1 activity</td>
<td>0.716 ± 0.124</td>
<td>1.213 ± 0.312 A</td>
<td>0.801 ± 0.142</td>
</tr>
</tbody>
</table>

*p < 0.05 versus basal values. Data are given as means ± SEM. ERK phosphorylation was determined by scanning densitometry after immunoblot analysis, and data are expressed in arbitrary density units. ERK and MEK1 activity are expressed as disintegrations per minute relative to ERK or MEK1 protein content determined by scanning densitometry following immunoblot analysis.

ulation of glycogen synthase activity was positively correlated with systemic glucose disposal. This has been interpreted to indicate that glucose stored as glycogen in skeletal muscle is a predominant pathway of insulin-stimulated glucose disposal (1, 5). Second, insulin stimulation of the association of the p85 regulatory subunit of PI 3-kinase with IRS-1 also was significantly correlated with insulin-stimulated glucose disposal, independent of the correlation of glycogen synthase activity with glucose disposal. Although insulin stimulation of IRS-1 tyrosine phosphorylation was correlated with both p85 and PI 3-kinase activity associated with IRS-1, only p85 association with IRS-1 was independently correlated with glucose disposal. These analyses provide evidence that decreased association of p85 with IRS-1 could be a key abnormality related to skeletal muscle insulin resistance.

This study was also undertaken to assess the effect of a single session of moderate intensity exercise on insulin action in the whole body and on a cellular level. Vigorous exercise increases insulin sensitivity (29). However, in the present study, moderate exercise (about 65% of VO2max) was used because such exercise is more realistic in everyday life for the average diabetic patient. Patients were studied 24 hours after the exercise bout to remove any confounding acute effects of exercise such as increased muscle blood flow or other systemic effects. Despite the moderate nature of this exercise, there were significant effects on muscle. Glycogen synthase activity and MAP kinase pathway activity were increased, and insulin receptor and IRS-1 tyrosine phosphorylation in response to insulin were improved. Moreover, basal HGP was normalized in the diabetic patients. Therefore even a mild exercise session can have beneficial effects in type 2 diabetics. Despite this, in diabetic patients, exercise did not improve the ability of insulin to increase either the rate of glucose disposal or the association of PI 3-kinase with IRS-1. Given that the association of PI 3-kinase with IRS-1 is a key rate-limiting step in insulin action, it is not surprising that exercise also did not improve insulin’s ability to stimulate glucose uptake. Exercise increases the activity of glycogen synthase as well as its sensitivity to activation by insulin (10, 44). This was clearly the case in the present study, as exercise increased basal and insulin-stimulated glycogen synthase activity to nearly normal levels in the type 2 diabetics. The fact that exercise did not increase insulin-stimulated glucose uptake provides clear evidence that normal insulin activation of skeletal muscle glycogen synthase is insufficient to increase insulin-stimulated glucose uptake. Therefore, even though it is possible to increase glucose uptake by overexpressing glycogen synthase in transgenic mice (45), it seems that an increase in glycogen synthase activity alone is insufficient to increase glucose disposal in humans. This is consistent with studies using nuclear magnetic resonance spectroscopy (46) or mathematical modeling of glucose tracer kinetics (3) that have found either glucose transport or glucose phosphorylation to determine the rate of glucose uptake in humans.

Other studies, using more intense exercise in healthy human volunteers (47) or rodents (25), or a single bout of moderate exercise in healthy humans (27), also failed to find an effect of exercise on insulin receptor signaling. The present results with respect to PI 3-kinase activity are consistent with these studies, although the finding of increased insulin receptor and IRS-1 tyrosine phosphorylation in response to insulin differs from those earlier results. One major difference that could explain this is that profoundly insulin-resistant subjects were used in the current study, whereas earlier investigations used healthy subjects (47). Regardless, the increases in insulin receptor and IRS-1 tyrosine phosphorylation that were observed here were not sufficient to increase insulin-stimulated glucose uptake. In contrast to the lack of effect of exercise on insulin signaling through the PI 3-kinase pathway, exercise increased the ability of insulin to stimulate ERK1/2 and MEK1 activity in the insulin-resistant patients. Because the role of the MAP kinase pathway in the various effects of insulin remains obscure, the significance of this effect of exercise is not clear. It is possible that the exercise-induced increase in MAP kinase activity is associated with a training response of skeletal muscle.

In summary, the present study shows that in insulin-resistant subjects with obesity or type 2 diabetes, there is profound insulin resistance in the PI 3-kinase pathway of insulin receptor signaling, whereas the MAP kinase pathway is normal. Moreover, in type 2 diabetes, a single bout of moderate-intensity exercise improves insulin receptor and IRS-1 tyrosine phosphorylation but does not increase insulin stimulation of the association of PI 3-kinase with IRS-1; nor does it increase insulin-stimulated glucose uptake. The abnormality in association of
PI 3-kinase with IRS-1 in insulin-resistant patients appears to be an significant defect that may result in decreased insulin-stimulated glucose disposal.

Acknowledgments

The expert technical assistance of A. Barrentine, K. Camp, J. Finlayson, G. Gomez, C. Muñoz, S. Taylor, and E. Landaker is gratefully acknowledged. P. Wolf and N. Diaz provided skilled nursing assistance. These studies were supported by grants from the National Institutes of Health (R01DK47936 to L.J. Mandarino, and R01DK24092 to R.A. DeFronzo), a VA Merit Award (R.A. DeFronzo), DK02526 (M.E. Patti), R01DK33201 (C.R. Kahn), The Markey Charitable Trust, RR-01346 (General Clinical Research Center, Audie L. Murphy Veterans Hospital), and a grant from the American Diabetes Association (L.J. Mandarino).